Integrating ultrasound and serum indicators for evaluating outcomes of targeted immunotherapy in advanced liver cancer

Figure 4 Receiver operating characteristic curves for the Target Immunotherapy Predictive Model and comparator models. A: Internal training cohort shows Target Immunotherapy Predictive Model (TIPM) achieving superior discrimination with an area under the curve (AUC) of 0.895; B: Internal validation cohort demonstrates TIPM maintaining the highest predictive performance (AUC 0.907) compared to alternative models; C: External validation cohort confirms TIPM’s consistent discriminative advantage (AUC 0.899). All curves illustrate TIPM’s robust performance superiority across different patient populations. ROC: Receiver operating characteristic; AUC: Area under the curve; TIPM: Target Immunotherapy Predictive Model; TNM: Tumor-node-metastasis; BCLC: Barcelona Clinic Liver Cancer; CNLC: China Liver Cancer; HKLC: Hong Kong Liver Cancer; CRAFITY: C-reactive protein and alpha-fetoprotein in immunotherapy.